Figure 2
Modulation of HBV infection by EGF. (A) Relative HBV DNA level in HepG2-NTCP cells at 2 ng/ml, 10 ng/ml and 50 ng/ml of EGF with/without 2.5 µg/ml anti-EGF antibody. The result is shown as the mean ± SEM of 3 independent experiments. **p < 0.01, ***p < 0.001. (B) Southern blot analysis of HBV DNA fractions obtained from HepG2-NTCP cells infected with HBV at post-infection day 7. (C) Relative HBV DNA level in HepG2-NTCP cells at 0 ng/ml, 1 ng/ml, 2 ng/ml, 5 ng/ml, 10 ng/ml, 25 ng/ml, 50 ng/ml and 100 ng/ml of EGF in HBV internalization assay. The result is shown as the mean ± SEM of 3 independent experiments. The result is shown as the mean ± SEM of 3 independent experiments. The significant difference was determined in each group compared with the control group. *p < 0.05, ***p < 0.001. (D) Relative HBV DNA level in primary human hepatocytes at 0 ng/ml, 1 ng/ml, 2 ng/ml, 5 ng/ml, 10 ng/ml, 25 ng/ml, 50 ng/ml and 100 ng/ml of EGF. The result is shown as the mean ± SEM of 3 samples in one experiment. The significant difference was determined in each group compared with the control group. *p < 0.05, ***p < 0.001. (E) Relative HBsAg level in iPS-hepatocytes at 0 ng/ml, 1 ng/ml, 2 ng/mL, 5 ng/ml, 10 ng/ml, 20 ng/ml, and 50 ng/ml of EGF in HBV infection assay. The result is shown as 5 independent experiments.
